Kyverna Therapeutics, Inc. (KYTX)Healthcare | Biotechnology | Emeryville, United States | NasdaqGS
8.06 USD
+0.19
(2.351%)
⇧
(June 12, 2026, 4 p.m.
EDT)
After hours: 8.21 +0.15 (1.924%) ⇧ (June 12, 2026, 6:36 p.m. EDT) |
Hot Take ↕ | June 7, 2026, 3:20 a.m. EDT
The investment case here is fractured between a desperate search for a turnaround and a stark reality check on the business fundamentals. On the surface, the catalysts are compelling: the company recently raised $100 million via a public offering, appointed a new CFO, and reported positive early trial data for its RA cell therapy. These events explain the recent 41% monthly surge and the strong 'strong buy' analyst consensus. However, the market has already priced in this optimism, driving the stock up significantly from its lows while the underlying financials remain deeply distressed. The company is burning cash aggressively, with negative free cash flow and a trailing EPS of -$3.27. The balance sheet, while currently bolstered by the fresh capital, shows negative returns on assets and equity. The price action confirms this tension; despite the positive news, the stock is still down 74% year-to-date, suggesting the market views the current valuation as insufficient to bridge the gap between the biotech pipeline and profitability. For a short-term trader, the heavy options activity at the $10 strike offers a chance for a bounce, but the lack of a dividend and the deteriorating operational metrics make this a high-risk speculative vehicle rather than a sound investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.067191 |
| MSTL | 0.071436 |
| AutoTheta | 0.072368 |
| MSTL_116 | 0.080867 |
| AutoARIMA | 0.083012 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 1.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.593 |
| Excess Kurtosis | 0.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.259 |
| Market Cap | 489,705,440 |
| Forward P/E | -2.73 |
| Beta | 1.96 |
| Website | https://kyvernatx.com |
As of June 7, 2026, 3:20 a.m. EDT: Speculators are positioning for a volatile range-bound outcome rather than a directional breakout. In the near term (June/July), heavy open interest sits at the $10 strike for both calls and puts, creating a wall of resistance and support around the current price. However, looking further out to December, there is a distinct divergence: massive volume and open interest in deep out-of-the-money calls ($10, $12.50) suggests a bullish 'lottery ticket' bet on a recovery, while significant put buying at the $2.50 strike indicates a hedge against a catastrophic collapse. The implied volatility is elevated across all expirations, reflecting uncertainty about whether the stock will find a floor or continue its decline.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.557143 |
| Address1 | 5,980 Horton Street |
| Address2 | Suite 550 |
| All Time High | 30.6 |
| All Time Low | 1.78 |
| Ask | 10.11 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 746,910 |
| Average Daily Volume3 Month | 935,801 |
| Average Volume | 935,801 |
| Average Volume10Days | 746,910 |
| Beta | 1.956 |
| Bid | 5.94 |
| Bid Size | 2 |
| Book Value | 3.231 |
| City | Emeryville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.055 |
| Current Ratio | 8.146 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,780,012,800 |
| Day High | 8.42 |
| Day Low | 7.855 |
| Debt To Equity | 17.259 |
| Display Name | Kyverna Therapeutics |
| Earnings Timestamp | 1,778,616,000 |
| Earnings Timestamp End | 1,786,564,800 |
| Earnings Timestamp Start | 1,786,564,800 |
| Ebitda | -162,136,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.77 |
| Enterprise Value | 287,014,432 |
| Eps Current Year | -2.87716 |
| Eps Forward | -2.95389 |
| Eps Trailing Twelve Months | -3.27 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.9953 |
| Fifty Day Average Change | -0.9403 |
| Fifty Day Average Change Percent | -0.10453236 |
| Fifty Two Week Change Percent | 155.7143 |
| Fifty Two Week High | 13.67 |
| Fifty Two Week High Change | -5.615 |
| Fifty Two Week High Change Percent | -0.41075346 |
| Fifty Two Week Low | 2.52 |
| Fifty Two Week Low Change | 5.5350003 |
| Fifty Two Week Low Change Percent | 2.1964288 |
| Fifty Two Week Range | 2.52 - 13.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,707,489,000,000 |
| Float Shares | 35,180,365 |
| Forward Eps | -2.95389 |
| Forward P E | -2.7269127 |
| Free Cashflow | -93,763,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 130 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -126,360,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.070989996 |
| Held Percent Institutions | 0.74301004 |
| Implied Shares Outstanding | 60,795,212 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-02-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. |
| Long Name | Kyverna Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 489,705,440 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_650816865 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -156,400,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 489,401,456 |
| Number Of Analyst Opinions | 5 |
| Open | 7.9 |
| Operating Cashflow | -150,394,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 925 2492 |
| Post Market Change | 0.15499973 |
| Post Market Change Percent | 1.9242673 |
| Post Market Price | 8.21 |
| Post Market Time | 1,781,303,787 |
| Previous Close | 7.87 |
| Price Eps Current Year | -2.799636 |
| Price Hint | 2 |
| Price To Book | 2.4930363 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.968 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.185 |
| Regular Market Change Percent | 2.3507 |
| Regular Market Day High | 8.42 |
| Regular Market Day Low | 7.855 |
| Regular Market Day Range | 7.855 - 8.42 |
| Regular Market Open | 7.9 |
| Regular Market Previous Close | 7.87 |
| Regular Market Price | 8.055 |
| Regular Market Time | 1,781,294,401 |
| Regular Market Volume | 646,616 |
| Return On Assets | -0.39548 |
| Return On Equity | -0.74549 |
| Sand P52 Week Change | 0.23177934 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 60,795,212 |
| Shares Percent Shares Out | 0.094399996 |
| Shares Short | 5,739,106 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 5,161,190 |
| Short Name | Kyverna Therapeutics, Inc. |
| Short Percent Of Float | 0.1112 |
| Short Ratio | 6.71 |
| Source Interval | 15 |
| State | CA |
| Symbol | KYTX |
| Target High Price | 33.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 30.4 |
| Target Median Price | 32.0 |
| Total Cash | 236,446,000 |
| Total Cash Per Share | 3.889 |
| Total Debt | 33,755,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.773025 |
| Two Hundred Day Average Change | 0.28197527 |
| Two Hundred Day Average Change Percent | 0.036276132 |
| Type Disp | Equity |
| Volume | 646,616 |
| Website | https://kyvernatx.com |
| Zip | 94,608 |